Aurinia Pharmaceuticals News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

24.08.22	Pre-market Movers: LGO, NERV, TMDX, BBBY, FTCH… (RTTNews)
04.08.22	Aurinia Reports Second Quarter and Six Months 2022 Financial and Operational Results (Businesswire)
03.08.22	Ausblick: Aurinia Pharmaceuticals mit Zahlen zum abgelaufenen Quartal (finanzen.net)
01.08.22	Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
26.07.22	Aurinia Pharmaceuticals Notification Regarding Inter Partes Patent Review (Businesswire)
25.07.22	Aurinia Pharmaceuticals to Release Second Quarter 2022 Financial and Operational Results on August 4, 2022 (Businesswire)
22.07.22	Aurinia Pharma Gets Positive CHMP Opinion For LUPKYNIS For Active Lupus Nephritis Treatment (RTTNews)
22.07.22	Aurinia Announces Positive CHMP Opinion for LUPKYNIS® (voclosporin) for the Treatment of Adults with Active Lupus Nephritis in Europe (Businesswire)
14.07.22	Aurinia Announces the Addition of Three Seasoned Executive Leaders to Advance Company Strategy and Performance (Businesswire)
10.06.22	AUPH FINAL DEADLINE ALERT: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Aurinia Pharmaceuticals Inc. Investors with Losses to Secure Counsel Before Important June 14 Deadline in Securities Class Act... (PR Newswire)
06.06.22	Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
03.06.22	Aurinia Presents Data Demonstrating LUPKYNIS® (voclosporin) is Effective in Achieving Proteinuria Treatment Targets in Lupus Nephritis Defined by EULAR/ERA Recommendations (Businesswire)
31.05.22	ROSEN, A LEADING AND RANKED FIRM, Encourages Aurinia Pharmaceuticals Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AUPH (PR Newswire)
25.05.22	AUPH INVESTOR NEWS: TOP RANKED ROSEN LAW FIRM Encourages Aurinia Pharmaceuticals Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AUPH (PR Newswire)
20.05.22	Aurinia Presents Results from the Two-Year AURORA 2 Continuation Study at the 2022 European Renal Association (ERA) Congress (Businesswire)
16.05.22	Aurinia Pharmaceuticals Announces Presentations at the 2022 ERA Congress and the 2022 EULAR Congress (Businesswire)
15.05.22	ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Aurinia Pharmaceuticals Inc. Investors With Losses Over $100K to Secure Counsel Before Important Deadline in Securities Class Action - AUPH (PR Newswire)
10.05.22	Aurinia Reports First Quarter 2022 Financial and Operational Results (Businesswire)
09.05.22	ROSEN, A LEADING LAW FIRM, Encourages Aurinia Pharmaceuticals Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AUPH (PR Newswire)
09.05.22	Ausblick: Aurinia Pharmaceuticals veröffentlicht Zahlen zum vergangenen Quartal (finanzen.net)
06.05.22	Notice of New Dial-In Numbers for Aurinia Pharmaceuticals First Quarter 2022 Financial and Operational Results on May 10, 2022 (Businesswire)
02.05.22	Aurinia Pharmaceuticals to Release First Quarter 2022 Financial and Operational Results on May 10, 2022 (Businesswire)
30.04.22	ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Aurinia Pharmaceuticals Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AUPH (PR Newswire)
21.04.22	ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Aurinia Pharmaceuticals Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AUPH (PR Newswire)
19.04.22	Aurinia Announces Year-Two Commitment to Patient Navigation Grant Program to Address Barriers for Individuals Living with Lupus and Lupus Nephritis (Businesswire)
04.04.22	Aurinia Pharmaceuticals Announces Presentations at the 2022 National Kidney Foundation Spring Clinical Meetings (Businesswire)
27.03.22	AUPH INVESTOR NOTICE: ROSEN, A TOP RANKED LAW FIRM, Encourages Aurinia Pharmaceuticals Inc. Investors with Losses to Inquire About Securities Class Action Investigation - AUPH (PR Newswire)
15.03.22	ROSEN, SKILLED INVESTOR COUNSEL, Encourages Aurinia Pharmaceuticals Inc. Investors to Inquire About Securities Class Action Investigation - AUPH (PR Newswire)
03.03.22	Aurinia Pharmaceuticals to Present at Upcoming Investor Conferences (Businesswire)
28.02.22	Aurinia Reports Fourth Quarter and Full Year 2021 Financial Results and Company Updates (Businesswire)
27.02.22	Ausblick: Aurinia Pharmaceuticals gibt Ergebnis zum abgelaufenen Quartal bekannt (finanzen.net)
13.02.22	Erste Schätzungen: Aurinia Pharmaceuticals stellt Ergebnisse des abgelaufenen Quartals vor (finanzen.net)
03.02.22	Aurinia Pharmaceuticals to Present at the 11th Annual Leerink Global Healthcare Conference (Businesswire)
04.01.22	Aurinia Pharmaceuticals to Present at Upcoming January Investor Conferences (Businesswire)
09.12.21	Pre-market Movers: ENSC, RETA, CCNC, PEAR, SYTA… (RTTNews)
09.12.21	Aurinia Announces Positive Topline Results From the AURORA 2 Continuation Study of LUPKYNIS™ (voclosporin) for the Treatment of Adults With Active Lupus Nephritis (LN) (Businesswire)
22.11.21	Pre-market Movers: ASTR, VG, CEI, CMBM, PTNR… (RTTNews)
17.08.21	Aurinia Pharmaceuticals Declines 9% Following Acquisition Of Two Pipeline Assets (RTTNews)
03.08.21	Ausblick: Aurinia Pharmaceuticals gibt Ergebnis zum abgelaufenen Quartal bekannt (finanzen.net)
30.06.21	Aurinia Awards $250,000 in Grants to Support Patient Navigation Programs (Businesswire)
25.06.21	Aurinia Announces Licensing Partner Otsuka Filed Initial Marketing Authorization Application (MAA) for Voclosporin with the European Medicines Agency (EMA) (Businesswire)
14.06.21	Aurinia Announces Addition of Dr. Brinda Balakrishnan to the Board of Directors (Businesswire)
27.05.21	Aurinia Pharmaceuticals to Present at the Jefferies Virtual Healthcare Conference (Businesswire)
20.05.21	Aurinia To Present Supportive AURORA 2 Continuation Study Interim Analysis Demonstrating Long-Term Safety & Efficacy of LUPKYNIS™ (voclosporin) in Subjects with Lupus Nephritis (Businesswire)
14.05.21	Aurinia Pharmaceuticals to Participate in Two Upcoming Investor Conferences (Businesswire)
10.05.21	Aurinia Unveils Patient Navigation Grant Program to Address Access Barriers for Individuals Living with Lupus and Lupus Nephritis (Businesswire)
10.05.21	Aurinia Announces Publication of AURORA 1 Phase 3 Study Results with LUPKYNIS™ (voclosporin) in The Lancet (Businesswire)
06.05.21	Aurinia Reports First Quarter 2021 Financial Results and Recent Operational Highlights (Businesswire)
04.05.21	Ausblick: Aurinia Pharmaceuticals stellt Ergebnisse des abgelaufenen Quartals vor (finanzen.net)
28.04.21	Aurinia Pharmaceuticals to Release First Quarter 2021 Financial Results on May 6, 2021 (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Part Grp Hldg	1’263.50	2.89 %	K V
Sonova Hldg	312.10	2.66 %	K V
Novartis	93.68	2.32 %	K V
Geberit	526.80	1.97 %	K V
Roche Hldg G	254.30	1.27 %	K V
Kuehne+Nagel Int	209.50	0.72 %	K V
UBS Group	28.30	0.57 %	K V
Givaudan	3’933.00	0.36 %	K V
Nestle	76.00	0.05 %	K V
Lonza Grp	521.40	-0.04 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Aurinia Pharmaceuticals Inc

Aktien Top/Flop

Meistgelesene Nachrichten